| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 265.54M | 266.76M | 256.13M | 232.02M | 205.45M | 170.45M |
| Gross Profit | 150.16M | 150.82M | 145.13M | 128.76M | 117.28M | 94.00M |
| EBITDA | 31.66M | 31.24M | 30.09M | 23.44M | 36.72M | 13.75M |
| Net Income | 5.63M | 13.44M | 6.72M | -2.15M | 13.15M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 404.38M | 396.34M | 396.63M | 411.26M | 413.41M | 327.67M |
| Cash, Cash Equivalents and Short-Term Investments | 116.71M | 102.30M | 127.57M | 140.87M | 196.03M | 111.54M |
| Total Debt | 53.67M | 41.28M | 64.40M | 80.98M | 99.11M | 115.11M |
| Total Liabilities | 154.97M | 147.84M | 160.04M | 182.33M | 180.83M | 194.56M |
| Stockholders Equity | 249.49M | 248.58M | 236.65M | 228.96M | 232.58M | 133.10M |
Cash Flow | ||||||
| Free Cash Flow | 1.54M | 5.08M | 8.40M | -64.00K | 14.12M | 12.33M |
| Operating Cash Flow | 22.77M | 31.46M | 20.16M | 24.71M | 25.84M | 29.98M |
| Investing Cash Flow | -21.17M | -28.59M | -11.04M | -53.92M | -13.13M | -28.27M |
| Financing Cash Flow | -8.98M | -27.64M | -22.37M | -24.87M | 71.16M | -16.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $286.51M | 45.33 | 14.48% | 0.49% | 10.53% | 21.98% | |
| ― | $356.77M | 57.34 | 2.21% | ― | 3.63% | -48.48% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ― | $399.64M | ― | -55.85% | ― | 4.06% | 57.50% | |
| ― | $336.64M | ― | -3.84% | ― | -3.60% | 48.15% | |
| ― | $242.30M | 1.38 | ― | 11.68% | -17.17% | 497.89% | |
| ― | $211.81M | ― | -105.81% | ― | -10.85% | -15.09% |
On October 28, 2025, Materialise NV reported its financial results for the third quarter of 2025, highlighting a 2.2% increase in total consolidated revenue compared to the previous quarter, though a 3.5% decrease from the same period in 2024. The Materialise Medical segment achieved a record quarterly revenue growth of 10.3% year-over-year, despite macroeconomic challenges impacting overall revenue, particularly in the Manufacturing segment. The company maintained strong cash flow and a positive net result, with a net profit of 1,848 kEUR. CEO Brigitte de Vet-Veithen emphasized the company’s focus on cost control and continued R&D investments to ensure future growth, while acknowledging ongoing geopolitical and economic uncertainties.
Materialise NV reported a decrease in total revenue by 3.5% for the third quarter of 2025 compared to the same period in 2024, with a notable increase in their Medical segment revenue by 10.3%. Despite the revenue decline, the company saw an increase in cash flow from operating activities and a stronger net cash position. However, the operating result and net profit both decreased compared to the previous year, reflecting challenges in their Software and Manufacturing segments. The company’s strategic focus on the Medical segment is evident with increased R&D investments, which may influence future growth in this area.